Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: Rationale for their use in clinical cardiology

Marco L. Rossi, D. Zavalloni

Research output: Contribution to journalArticle

Abstract

The glycoprotein IIb/IIIa (GP IIb/IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb/IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb/IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

Original languageEnglish
Pages (from-to)703-709
Number of pages7
JournalMini-Reviews in Medicinal Chemistry
Volume4
Issue number7
Publication statusPublished - Sep 2004

Keywords

  • Acute coronary syndromes
  • Atherosclerotic plaque
  • Glycoprotein IIb/IIIa receptor
  • Percutaneous coronary intervention
  • Platelet aggregation inhibitors

ASJC Scopus subject areas

  • Chemistry(all)
  • Medicine (miscellaneous)
  • Pharmacology

Fingerprint Dive into the research topics of 'Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: Rationale for their use in clinical cardiology'. Together they form a unique fingerprint.

  • Cite this